Established in April 2011, the STA Pharmaceutical Co., Ltd. (“STA”), a WuXi AppTec subsidiary, is a global leading small molecule pharmaceutical development and manufacturing capability and technology platform company serving the life science industry, with operations in China and the United States. As a premier Contract Development and Manufacturing Organization (CDMO), STA offers worldwide partners efficient, flexible and high-quality solutions for small molecule Active Pharmaceutical Ingredients (APIs) and finished dosage forms.
Since its eastablishment, STA has been committed to providing high-quality and high-tech API-related services and products for worldwide partners. STA’s target type of pharmaceuticals is innovative medicine, namely New Molecular Entity (NME); its target treatment fields include anti-cancer, anti-AIDS, anti-Hepatitis C, hypolipidemic, pain relief, anti-diabetes, anti-bacterial infections, and anti-cystic fibrosis; its target medicine life cycle is from the clinical trial of innovative medicine to the sale of patented medicine. Based on technological R&D, STA provides customers with high-quality pharmaceutical R&D production services by virtue of years’ outcomes in the production process development and production flow control. It has established partnerships with globally renowned pharmaceutical R&D and production companies. It was awarded the honor of “Best Partner” for many years by large-scale pharmaceutical companies, such as Janssen, Merck and GSK.
It has built a world-class chemical laboratory facility with a total size of over 10,000 square meters in the Shanghai Waigaoqiao Free Trade Zone. This facility is equipped with the most advanced process safety laboratory and crystallization laboratory in China as well as domestically leading metal catalyst screening laboratory and enzyme catalysis process laboratory. This facility now has over 800 employees, over 70% of whom have a master's or doctoral degree. STA's R&D team employs many academic pacesetters who have years’ overseas study and working experience. These high-level talents have accelerated the building of STA’s internationally advanced R&D capacities, upgraded its laboratory management level, and established a research system in line with international standards.
STA has maintained a good growth momentum since its founding, witnessing a rapid increase in its sales revenue. In 2018, it realized a sales revenue of over 600 million RMB and a total profit of 150 million RMB. In the future, focusing on its own development, STA will also commit itself to promoting the innovative development of the global pharmaceutical industry by actively providing integrated solutions for medicine R&D and production, so as to improve health and pursue excellence.